Prof Tara Spires-Jones, president of the British Neuroscience Association, said the EMA’s decision will come as “a disappointment to many”.
But she said there were reasons to remain hopeful.
“Lecanemab has shown that it is possible to slow down disease progression, and research does work. Now we need to ramp up our efforts to discover new and safer treatments,” Prof Spires-Jones said.
Prof John Hardy, professor of neuroscience and group leader at the UK Institute for Dementia Research, University College London (UCL), said the decision could have unintended consequences.
“I am sure we will now see rich people with early Alzheimer’s disease flying to the US or other jurisdictions for treatment.”
Whilst in Egypt, Kushner also met Egyptian President Abdel Fattah al-Sisi. According to Israeli media…
The conflict there killed hundreds of thousands of people, displaced millions, and caused severe damage…
Iqra Wasim from Fishponds in Bristol has struggled with PMOS symptoms such as painful acne…
Prof Vaibhav Modgil, an andrologist and consultant urological surgeon for the NHS in Manchester, has…
Iran has called for the release of three Iranian pilots it said were captured by…
Eleven people have been killed in Israeli strikes in southern Lebanon, authorities say, in one…